IN8bio to Present at Biotech Showcase 2025 in San Francisco
IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on gamma-delta T cell therapies, has announced its participation in Biotech Showcase 2025 in San Francisco. CEO and co-founder William Ho will participate in two key events:
1. A panel discussion on 'The Battle Against Cancer: The Armamentarium Keeps Expanding' on Monday, January 13, 2025, at 8:00 AM PT
2. A corporate presentation on Tuesday, January 14, 2025, at 2:00 PM PT
Both events will take place at the Hilton San Francisco Union Square Hotel. The company's management will also be available for investor meetings from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference. A live webcast of the presentation will be available, and interested parties can register for the event through the provided links.
IN8bio (Nasdaq: INAB), un'azienda biofarmaceutica in fase clinica focalizzata sulle terapie con cellule T gamma-delta, ha annunciato la sua partecipazione al Biotech Showcase 2025 a San Francisco. Il CEO e co-fondatore William Ho parteciperà a due eventi chiave:
1. Una discussione panel su 'La Battaglia Contro il Cancro: L'Arsenale Continua ad Espandersi' lunedì 13 gennaio 2025, alle 8:00 AM PT
2. Una presentazione aziendale martedì 14 gennaio 2025, alle 2:00 PM PT
Entrambi gli eventi si svolgeranno presso l'Hilton San Francisco Union Square Hotel. La direzione dell'azienda sarà inoltre disponibile per incontri con gli investitori dal 13 al 16 gennaio 2025, durante la 43ª Conferenza Annuale J.P. Morgan Health Care. Sarà disponibile una trasmissione in diretta della presentazione, e le parti interessate possono registrarsi per l'evento attraverso i link forniti.
IN8bio (Nasdaq: INAB), una compañía biofarmacéutica en etapa clínica centrada en terapias con células T gamma-delta, ha anunciado su participación en el Biotech Showcase 2025 en San Francisco. El director ejecutivo y cofundador William Ho participará en dos eventos clave:
1. Una discusión panel sobre 'La Batalla Contra el Cáncer: El Arsenale Sigue Expandiéndose' el lunes 13 de enero de 2025, a las 8:00 AM PT
2. Una presentación corporativa el martes 14 de enero de 2025, a las 2:00 PM PT
Ambos eventos tendrán lugar en el Hilton San Francisco Union Square Hotel. La dirección de la compañía también estará disponible para reuniones con inversores del 13 al 16 de enero de 2025, durante la 43ª Conferencia Anual de Cuidado de la Salud de J.P. Morgan. Se transmitirá en vivo la presentación y las partes interesadas pueden registrarse para el evento a través de los enlaces proporcionados.
IN8bio (Nasdaq: INAB), 감마-델타 T 세포 치료에 중점을 둔 임상 단계의 생명공학 회사가 샌프란시스코에서 열리는 Biotech Showcase 2025에 참가한다고 발표했습니다. CEO이자 공동 설립자인 William Ho는 두 가지 주요 행사에 참석할 예정입니다:
1. '암과의 전투: 무기가 계속 확장되고 있다'에 대한 패널 토론이 2025년 1월 13일 월요일 오전 8시(PT)에 진행됩니다.
2. 2025년 1월 14일 화요일 오후 2시(PT)에 기업 발표가 있습니다.
두 행사 모두 힐튼 샌프란시스코 유니온 스퀘어 호텔에서 열립니다. 회사의 경영진은 또한 2025년 1월 13일부터 16일까지 열리는 제43회 J.P. Morgan 건강 관리 컨퍼런스 동안 투자자 회의에 참석할 수 있습니다. 발표는 실시간 웹캐스트로 제공되며, 관심 있는 분들은 제공된 링크를 통해 행사에 등록할 수 있습니다.
IN8bio (Nasdaq: INAB), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par cellules T gamma-delta, a annoncé sa participation au Biotech Showcase 2025 à San Francisco. Le PDG et co-fondateur William Ho participera à deux événements clés :
1. Une discussion en panel sur 'La Bataille Contre le Cancer : L'Arsenal Continue de S'Élargir' le lundi 13 janvier 2025, à 8h00 PT
2. Une présentation d'entreprise le mardi 14 janvier 2025, à 14h00 PT
Les deux événements auront lieu à l'Hilton San Francisco Union Square Hotel. La direction de l'entreprise sera également disponible pour des réunions avec des investisseurs du 13 au 16 janvier 2025, lors de la 43e Conférence Annuelle J.P. Morgan sur les soins de santé. Une diffusion en direct de la présentation sera disponible, et les parties intéressées peuvent s'inscrire à l'événement via les liens fournis.
IN8bio (Nasdaq: INAB), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf Gamma-Delta-T-Zelltherapien konzentriert, hat seine Teilnahme an der Biotech Showcase 2025 in San Francisco bekannt gegeben. CEO und Mitbegründer William Ho wird an zwei wichtigen Veranstaltungen teilnehmen:
1. Eine Podiumsdiskussion mit dem Titel 'Der Kampf gegen Krebs: Das Arsenal erweitert sich weiter' am Montag, den 13. Januar 2025, um 8:00 Uhr PT
2. Eine Unternehmenspräsentation am Dienstag, den 14. Januar 2025, um 14:00 Uhr PT
Beide Veranstaltungen finden im Hilton San Francisco Union Square Hotel statt. Das Management des Unternehmens wird auch für Investoren meetings vom 13. bis 16. Januar 2025 während der 43. J.P. Morgan Gesundheitskonferenz zur Verfügung stehen. Eine Live-Übertragung der Präsentation wird verfügbar sein, und interessierte Parteien können sich über die bereitgestellten Links für die Veranstaltung anmelden.
- None.
- None.
NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced William Ho, CEO and co-founder, will participate at Biotech Showcase 2025 on a panel on Monday, January 13, 2025, and present on Tuesday, January 14, 2025, at the Hilton San Francisco Union Square Hotel in San Francisco, CA. Details for the event are provided below.
Biotech Showcase, January 13 - 15, 2025
Panel: The Battle Against Cancer: The Armamentarium Keeps Expanding
- Date: Monday, January 13, 2025
- Time: 8:00 AM PT
- Track: Yosemite C (Ballroom Level)
Corporate presentation
- Date: Tuesday, January 14, 2025
- Time: 2:00 PM PT
- Track: Yosemite A (Ballroom Level)
- Live webcast: https://event.webcasts.com/starthere.jsp?ei=1703689&tp_key=9d7f185675
Interested parties can register to attend the event here: https://informaconnect.com/biotech-showcase/registration-options/
Additionally, IN8bio management will be in San Francisco from January 13-16, 2025, during the 43rd Annual J.P. Morgan Health Care Conference and will be available for meetings with investors. Individuals interested in meeting with IN8bio management can contact gdschulman@in8bio.com.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-100, is focused on AML evaluating haplo-matched allogeneic gamma-delta T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI gamma-delta T cells, in combination with standard of care, for glioblastoma. For more information about IN8bio, visit www.IN8bio.com.
Investors & Company Contacts
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@in8bio.com
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
FAQ
When and where will IN8bio (INAB) present at Biotech Showcase 2025?
What panel will IN8bio's CEO participate in at Biotech Showcase 2025?
How can investors meet with IN8bio management during the J.P. Morgan Healthcare Conference?
Where can I watch the live webcast of IN8bio's Biotech Showcase 2025 presentation?
How can I register to attend IN8bio's presentation at Biotech Showcase 2025?
